Taven 20

Indications of Taven 20

Taven 20 is indicated as an adjunct to diet for the reduction of elevated total cholesterol, LDL-cholesterol, apolipoprotein B, and triglycerides in patients with- Primary hypercholesterolemia- heterozygous familial and non-familial hypercholesterolemia and mixed dyslipidemia (Fredrickson types IIa and IIb) Elevated serum TG levels (Fredrickson type IV) Primary dysbetalipoproteinemia (Fredrickson type III) who do not respond adequately to diet. Homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (LDL apheresis) or if such treatments are unavailable.

 

Pharmacology of Taven 20

Atorvastatin may be a specific inhibitor of HMG-CoA reductase. This chemical is the rate-limiting protein mindful for the transformation of HMG-CoA to mevalonate, a forerunner of sterols, counting cholesterol. Atorvastatin brings down plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA reductase and cholesterol union within the liver and increments the number of hepatic LDL receptors on the cell surface for improved take-up and catabolism of LDL.

 

Dosage & Administration

Patients should be placed on a standard cholesterol-lowering diet before receiving Atorvastatinand should continue on this diet during treatment with Taven 20. The usual starting dose for all the indications is 10mg once daily. The doses range is 10 to 80 mg once daily. Doses should be individualized according to baseline LDL-C levels, the goal of therapy, and patient response. Adjustment of dosage should be made at intervals of 4 weeks or more. Doses may be given at any time of day with or without food.

 

Interaction of Taven 20

The risk of myopathy during treatment with other drugs in this class is increased with concurrent administration of cyclosporin, fibric acid derivatives, erythromycin, azole antifungals, or niacin (nicotinic acid). These risks may also occur when combining these drugs with Atorvastatin. No clinically significant interactions were seen when Atorvastatin was administered with antihypertensives and or hypoglycemic agents. Caution should also be exercised when Atorvastatin is administered with inhibitors of P450 3A4 (macrolide antibiotics and azole antifungals). The effect of inducers of cytochrome P450 3A4 (rifampicin or phenytoin) on Atorvastatin is unknown. Patients should be closely monitored if Atorvastatin is added to digoxin, erythromycin, oral contraceptives, colestipol, antacid, and warfarin. No interaction was found with cimetidine.

 

Contraindications

Taven 20 is contraindicated in patients with hypersensitivity to any component of this medication, active liver disease, or unexplained persistent elevations of serum transaminases, during pregnancy, while breastfeeding, and in women of child-bearing potential not using appropriate contraceptive measures.

 

Side Effects of Taven 20

Taven 20 is generally well tolerated. Adverse reactions have usually been mild and transient. Reversible myositis is a rare but significant side effect of statins. The statins also cause headache, altered liver function tests, and gastrointestinal effects including abdominal pain, flatulence, diarrhea, nausea, and vomiting. Thrombocytopenia, rash, and hypersensitivity reactions have been reported rarely. Other side effects are reported with Taven 20 therapy include insomnia, angioedema, anorexia, asthenia, paraesthesia, peripheral neuropathy, alopecia, pruritus, rash, impotence, chest pain, hypoglycemia, and hyperglycemia.

 

Pregnancy & Lactation

Taven 20 is contraindicated in pregnancy and while breastfeeding. Women of childbearing potential should use appropriate contraceptive measures. If the woman becomes pregnant while taking Atorvastatin, it should be discontinued.

 

Precautions & Warnings

Liver effects: Liver function tests should be performed before the initiation of treatment and periodically thereafter. Should an increase in ALT or AST of greater than 3 times the upper limit of normal persist, reduction of dose, or withdrawal of Atorvastatin be recommended? Atorvastatin should be used with caution in patients who consume substantial quantities of alcohol and/or have a history of liver disease. Skeletal muscle effects: Uncomplicated myalgia has been reported in Atorvastatin-treated patients. Atorvastatin therapy should be discontinued if markedly elevated CPK levels occur or myopathy is diagnosed or suspected. Should significant increases in CPK persist, reduction of dose or withdrawal of Atorvastatin is recommended? Rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with Atorvastatin and with other drugs in this class. Use in Special Populations Children: Treatment experience in a pediatric population with a dose of Atorvastatin up to 80 mg/day is limited. Geriatric (>70 years): The safety and efficacy of Atorvastatin in this population is as similar as < 70 years of age patients with the dose up to 80 mg/day. Renal Insufficiency: No dosage adjustment is required.

 

Therapeutic Class

Other Anti-anginal & Anti-ischaemic drugs, Statins Pharmacology Atorvastatin is a synthetic lipid-lowering agent. It is a selective, competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, an early and rate-limiting step in cholesterol biosynthesis.

 

Storage Conditions

Store in a cool dry place protected from light. Keep out of reach of children.

 

Pharmaceutical Name of Taven 20

Renata Limited

 

Generic of Taven 20

Atorvastatin Calcium

 

Related Products

• Atova 20
• Atasin 20
• Anzitor 20
• Orva 20